Improving outcomes and combating AMR by giving the best drug every time
iFAST is addressing the $4bn (& growing) Antimicrobial Susceptibility Testing (AST) market.
We have a test that is up to 10x faster and cheaper than the gold standard, delivering results in 4 hours for urine samples and 8 hours for sepsis, saving lives and reducing the spread of antimicrobial resistance.
Improving outcomes and combating AMR by giving the best drug every time
iFAST is addressing the $4bn (& growing) Antimicrobial Susceptibility Testing (AST) market.
We have a test that is up to 10x faster and cheaper than the gold standard, delivering results in 4 hours for urine samples and 8 hours for sepsis, saving lives and reducing the spread of antimicrobial resistance.
The Problem
Bacteria are increasingly resistant to antibiotics – resistance levels are 20% - 98% and unpredictable. Current Antimicrobial Susceptibility Testing (AST) takes 48 -72 hours – patients deteriorate whilst waiting for the correct drug.
Prescribing inappropriate antibiotics leads to the spread of resistant infections, sepsis and death
Antimicrobial resistance (AMR) caused over 1 million deaths in 2019 – more than malaria and AIDS combined
iFAST reduces AST test time from 48+ to 4 hours
Blood/urine sample Incubated
Sample incubated for
a few hours then exposed to
range of antibiotics
Test itself takes
2 minutes
After a further 1 hour incubation, reader scans 10,000 individual bacteria
RESISTANT/
SUSCEPTIBLE Output
iFAST reader determines
optimum antibiotic for clinician to prescribe
optimum antibiotic for clinician to prescribe
The Benefits of iFAST
Speed
Results in only 4 hours (urine)
– 8 hours (blood) from raw sample
High throughput
Each reader performs
> 100 tests/day
Cost
Cheaper than current
gold standard methods
Small lab footprint
Reader is only 600x600mm
and fits neatly on a lab bench
Each sample analysed in <2 mins
The electrical properties of single bacteria are measured at high speed in a microfluidic chip.
Experienced and committed team
Dr Toby King
CEO
Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Prof Hywel Morgan
CTO
Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Dr Dan Spencer
VP Engineering
Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Prof Mark Sutton
Advisory Board Chair
Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Research system will be available in 2023, with clinical system expected to launch in 2024.
To find out more
If you would like find out more please send us
an email and we will get in touch.
Find our presentation, nature paper below & synopsis for hospitals below.
